Clinical trial

Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer

NCT07717099

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-09-01

PhasePHASE2

Study timeline

Study start (estimated)2026-09-01Date precision: month

Registry last updated2026-07-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Hormone-Sensitive Prostate Canceunresolved

Interventions

Ra223DRUG

Darolutamide Oral TabletDRUG · verified · RxNorm: darolutamide Oral Tablet

Androgen Deprivation Therapy (ADT)OTHER

Sponsors & collaborators

Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARDlead sponsor

Bayercollaborator

MFARcollaborator

Mapped research locations

MadridSpain4 BarcelonaSpain2 ValenciaSpain1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07717099 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.